➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

Docket   Start Trial Date Filed 2019-03-18
Court District Court, N.D. Illinois Date Terminated 2020-06-30
Cause 15:1 Antitrust Litigation Assigned To Manish Suresh Shah
Jury Demand Both Referred To
Patents 7,820,799; 8,093,045; 8,663,945; 8,911,964; 8,926,975; 8,961,973; 8,986,693; 9,018,361; 9,067,992; 9,085,619; 9,090,689; 9,090,867; 9,096,666; 9,187,559; 9,255,143; 9,266,949; 9,359,434; 9,365,645; 9,512,216
Attorneys David C. Giardina
Firms Freed Kanner London Millen LLC
Link to Docket External link to docket
Biologic Drugs cited in In Re: Humira (Adalimumab) Antitrust Litigation
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-08-09 109 Amended Complaint in light of U.S. Patent No. 5,429,746 and a publication of U.S. Patent No. 7,820,799. Although it does…second patent not patentably distinct from claims in a first patent.”19 57. Patent prosecutions…another of 20 patents or patent applications. 131. The patent applications and patents fall roughly…’044 patent, the ’322 patent, and the ’491 patent in the U.K. Yet, as it did with the ’656 patent, prior…of AbbVie’s use patents and found three patents invalid due to obviousness: U.S. Patent No. 8,889,135; External link to document
2019-10-11 124 Office. Compl. at 41; id. ¶¶ 114-20 (U.S. Patent Nos. 8,093,045; 8,911,964; 9,090,867; and 9,018,361). But… the United States Patent Office has granted, dozens of U.S. patents. The Patent Office has recognized…AbbVie’s patents, several biosimilar companies challenged the patents by petitioning the Patent Trial and…included two overlapping patents, AbbVie sued Amgen for patent infringement on 10 patents, including one for…adalimumab patents, including patents that expire after 2023. If even a single valid patent claim would External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.